MedTrace Logo

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

NCT06239194 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 285

Last updated 2026-05-06

No results posted yet for this study

Summary

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

Conditions

Interventions

DRUG

MDX2001

MDX2001 intravenous infusion

Sponsors & Collaborators

  • ModeX Therapeutics, An OPKO Health Company

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-12
Primary Completion
2028-08-31
Completion
2029-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06239194 on ClinicalTrials.gov